Arpit Vyas, MD, Dishman Pharma aims at working with EBITDA margins not below USD 25-30 percent and expects to pare down the company debt by Rs 70-80 crore this calendar year.
first published: Oct 3, 2013 11:50 am
A collection of the most-viewed Moneycontrol videos.
Monday Mayhem in markets| Brent surges 18%, Global markets slide 2-8% | Nifty Set for Gap Down Open
PM Modi Speech: PM Modi Accuses TMC of Insulting President Murmu and Constitution
India Markets Not Cheap Right Now? CIO Rajesh Bhatia Flags Risks
Will AI Replace Financial Advisors? Future of Investing Explained
